Cardlytics (CDLX)
(Delayed Data from NSDQ)
$4.05 USD
+0.14 (3.58%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $4.05 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.05 USD
+0.14 (3.58%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $4.05 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Zacks News
Jacobs Solutions (J) Q3 Earnings Beat Estimates
by Zacks Equity Research
Jacobs Solutions (J) delivered earnings and revenue surprises of 0.51% and 3.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cardlytics (CDLX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardlytics (CDLX) delivered earnings and revenue surprises of 44.19% and 10.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Spotify (SPOT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Spotify (SPOT) delivered earnings and revenue surprises of -111.25% and 2.28%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Cardlytics (CDLX) Surges 13.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Cardlytics (CDLX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CleanSpark (CLSK) Soars 8.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
CleanSpark (CLSK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Is Cardlytics (CDLX) Stock Outpacing Its Business Services Peers This Year?
by Zacks Equity Research
Here is how Cardlytics (CDLX) and Trane Technologies (TT) have performed compared to their sector so far this year.
Does Cardlytics (CDLX) Have the Potential to Rally 49.25% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 49.3% upside potential for Cardlytics (CDLX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Cardlytics (CDLX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardlytics (CDLX) delivered earnings and revenue surprises of 37.50% and 4.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Cardlytics (CDLX) Recently Broke Out Above the 200-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 200-day simple moving average?
Earnings Preview: NV5 Global (NVEE) Q1 Earnings Expected to Decline
by Zacks Equity Research
NV5 (NVEE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Cardlytics (CDLX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cardlytics (CDLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardlytics (CDLX) Soars 80.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Cardlytics (CDLX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Strength Seen in Symbotic Inc. (SYM): Can Its 9.5% Jump Turn into More Strength?
by Zacks Equity Research
Symbotic Inc. (SYM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Cardlytics (CDLX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cardlytics (CDLX) delivered earnings and revenue surprises of 45.28% and 2.16%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Cardlytics (CDLX): Can Its 12.1% Jump Turn into More Strength?
by Zacks Equity Research
Cardlytics (CDLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why Cardlytics (CDLX) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Cardlytics (CDLX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
After Plunging 52% in 4 Weeks, Here's Why the Trend Might Reverse for Cardlytics (CDLX)
by Zacks Equity Research
Cardlytics (CDLX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Cardlytics (CDLX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cardlytics (CDLX) delivered earnings and revenue surprises of 7.41% and 2.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardlytics (CDLX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cardlytics (CDLX) delivered earnings and revenue surprises of -20.37% and 1.59%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardlytics (CDLX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardlytics (CDLX) delivered earnings and revenue surprises of 44.93% and 3.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Seagate (STX) Misses Q3 Earnings Estimates
by Zacks Equity Research
Seagate (STX) delivered earnings and revenue surprises of -3.21% and 0.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardlytics (CDLX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardlytics (CDLX) delivered earnings and revenue surprises of 63.41% and 16.64%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Copart, Inc. (CPRT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Copart, Inc. (CPRT) delivered earnings and revenue surprises of 5.77% and 10.24%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardlytics (CDLX) Soars 6.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Cardlytics (CDLX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Cardlytics (CDLX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardlytics (CDLX) delivered earnings and revenue surprises of 34.00% and 4.14%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?